Drug intelligence / Profile preview

MCM vaccine

Development stage
Preclinical
Lead developer
University of Florida
Modality
Hydrogel Systems → Drug Delivery Systems, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration
Subcutaneous
01

Overview

**MCM vaccine** is an investigational, preclinical tumor-mRNA cancer vaccine developed at the University of Florida for glioblastoma and glioma. It consists of total tumor-derived mRNA organized in an \"onion-like\" microgel-chemokine-mRNA complex and administered subcutaneously. In a murine intracranial glioma model, the formulation promoted intratumoral immune activation, including dendritic-cell and natural-killer-cell recruitment, T-cell activation and infiltration, and pro-inflammatory M1-like microglial reprogramming. Its antitumor activity was associated with tumor CCL4 upregulation and signaling through the CCL4-CCR5 axis; CCL4 blockade eliminated the observed survival benefit.

Other names
MCMMCM vaccinemicrogel-chemokine-mRNA complex
02

Targets

CCR3 (C-C chemokine receptor type 3)CCR5 (C-C chemokine receptor type 5)

Beyond the preview

Go deeper on MCM vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MCM vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call